Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05439759 · ClinicalTrials.gov registry record · NA
Factors in Learning And Plasticity: Healthy Vision
A NA study of Macular Degeneration and Central Visual Impairment, sponsored by University of Alabama at Birmingham.
- Active
- Registry status
- NA
- Development phase
- 120
- Enrollment target
- 2
- Study locations
NCT05439759: Active NA study of Macular Degeneration and Central Visual Impairment, sponsored by University of Alabama at Birmingham.
NCT05439759 is a NA study of Macular Degeneration and Central Visual Impairment that is active but no longer recruiting, run by University of Alabama at Birmingham. The registered enrollment target is 120 participants, below the 174-participant average among 26 other Macular Degeneration trials with a reported enrollment target (31% lower). The trial reports 2 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05439759, a NA study of Macular Degeneration and Central Visual Impairment, is active but no longer recruiting, sponsored by University of Alabama at Birmingham.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 120 participants
- Enrollment target
- 2
- Study locations
Study Summary
A greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has the potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the National Eye Institute (NEI) to support research on visual disorders, mechanisms of visual function, and preservation of sight. The comparison of different training and outcome factors is in line with the National Institute of Mental Health (NIMH) Research Domain Criteria (RDOC) framework and studies in an aging population are consistent with the mission of the National Institute on Aging (NIA).
Primary Outcome
The ratio of the crowding threshold along the axis connected to the fovea vs. along the orthogonal axis.
Conditions Studied
Interventions
- BEHAVIORAL Condition 1: Training visual sensitivity
- BEHAVIORAL Condition 2: Training spatial integration
- BEHAVIORAL Condition 3: Training spatial attention
- BEHAVIORAL Condition 4: Combination training
Study Locations (2)
Alabama
- UAB - Birmingham
California
- University of California, Riverside - Riverside
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2022-10-24 |
| Est. Completion | 2026-11 |
| Phase | NA |
What the registry record for NCT05439759 still lists
NCT05439759 is an interventional study that assigns participants to a tested intervention. The registered 120 participants enrollment target is mid-sized for trials with a published cap, below the 174-participant average among 26 other Macular Degeneration trials with a reported enrollment target (31% lower).
The record links to 2 conditions, with Macular Degeneration appearing as the primary indexed condition, and to 4 interventions - of which Condition 1: Training visual sensitivity is the first listed.
NCT05439759 reports a single indexed study location in Alabama, California.
Frequently Asked Questions
What is clinical trial NCT05439759 about?
NCT05439759 is a clinical study titled "Factors in Learning And Plasticity: Healthy Vision". A greater understanding of plasticity after central vision loss can inform new therapies for treating low vision and has the potential to benefit millions of individuals suffering from low vision. The treatment of low vision is particularly relevant to the mission of the National Eye Institute (NEI)...
What is the current status of trial NCT05439759?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 120 participants. The study started on 2022-10-24. Estimated completion is 2026-11.
What conditions does trial NCT05439759 study?
This clinical trial studies the following conditions: Macular Degeneration, Central Visual Impairment.
What interventions are being tested in trial NCT05439759?
The interventions under investigation include: Condition 1: Training visual sensitivity (BEHAVIORAL), Condition 2: Training spatial integration (BEHAVIORAL), Condition 3: Training spatial attention (BEHAVIORAL), Condition 4: Combination training (BEHAVIORAL).
Who is sponsoring clinical trial NCT05439759?
This trial is sponsored by University of Alabama at Birmingham, which has 1,160 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05439759 being conducted?
This trial has 2 study locations across Alabama, California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Macular Degeneration
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05439759's enrollment target sits among peer trials
120 10th of 26 higher than 16 of 26 other Macular Degeneration trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Macular Degeneration trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Factors in Learning And Plasticity: Macular Degeneration
RECRUITING · NA
-
Pilot Study: A Randomized Trial Of Anesthetic Agents For Intravitreal Injection
COMPLETED · NA
-
Evaluation of a New Eye-specific Multivitamin Formula in Participants at Risk of Age-related Macular Degeneration (AMD)
COMPLETED · NA
-
A Long-term Extension Study of JNJ-81201887 (AAVCAGsCD59) Parent Studies in Participants With Geographic Atrophy (GA) Secondary to Age-related Macular Degeneration (AMD)
RECRUITING · Phase 2
-
Feasibility and Safety of MB-102 in Ocular Angiography as Compared to Fluorescein Sodium
RECRUITING · Early Phase 1
-
A Study to Learn How Avacincaptad Pegol (Izervay™) is Used in Clinical Practice in People Who Have Geographic Atrophy
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01174108 · 120 participants · Phase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
- NCT01627301 · 120 participants · NA
Sympathetic Overactivity in Post-traumatic Stress Disorder
- NCT02025023 · 120 participants · Phase 3
Local 5-Fluorouracil Injection for the Treatment of Chalazia: A Prospective, Comparative Study
- NCT02128906 · 120 participants · Phase 2
Radiotherapy With Cisplatin vs. Docetaxel-cetuximab in HNSCC: ERCC1 Biomarker Enrichment and Interaction Design
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI